menu

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
Drug Info Rounds

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

close
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
RestartResume
Choose a format
Media formats available:
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

    Released May 18, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

    Released May 18, 2017

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/28/20